Biomarin Pharmaceutical Inc (BMRN): Next-Year EPS Estimate 34.19%
As of 2026-06-04, Biomarin Pharmaceutical Inc (BMRN) has a next-year EPS growth estimate of 34.19%.
On 2026-06-02, analyst consensus for BMRN's next-year EPS growth shifted from 34.00% to 34.19% — a positive change of 0.19 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions. Current-year growth is projected at 171.84%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 34.19%
- EPS growth this year
- 171.84%
- EPS next quarter (est)
- $0.95
- Last price
- $56.47
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 34.19% | 171.84% | $0.95 | $56.47 |
| 2026-06-03 | 34.19% | 171.84% | $0.95 | $54.66 |
| 2026-06-02 | 34.19% | 171.84% | $0.95 | $53.32 |
| 2026-06-01 | 34.00% | 171.43% | $0.95 | $55.03 |
| 2026-05-31 | 34.00% | 171.43% | $0.95 | $57.29 |
| 2026-05-28 | 34.00% | 171.43% | $0.95 | $52.74 |
| 2026-05-27 | 34.00% | 171.43% | $0.95 | $52.38 |
| 2026-05-26 | 34.00% | 171.43% | $0.95 | $52.88 |
| 2026-05-25 | 34.00% | 171.43% | $0.95 | $54.09 |
| 2026-05-24 | 34.00% | 171.43% | $0.95 | $54.09 |
| 2026-05-21 | 33.81% | 171.92% | $0.97 | $54.10 |
| 2026-05-20 | 33.40% | 150.31% | $0.89 | $50.20 |
| 2026-05-19 | 39.40% | 116.94% | $0.79 | $49.81 |
| 2026-05-18 | 42.30% | 109.22% | $0.77 | $49.67 |
| 2026-05-17 | 42.43% | 109.22% | $0.77 | $51.81 |
| 2026-05-14 | 37.79% | 116.26% | $0.77 | $53.24 |
| 2026-05-13 | 37.79% | 116.26% | $0.77 | $53.41 |
| 2026-05-12 | 37.79% | 116.26% | $0.77 | $52.88 |
| 2026-05-11 | 37.79% | 116.26% | $0.77 | $52.58 |
| 2026-05-10 | 35.58% | 119.47% | $0.81 | $54.06 |
| 2026-05-07 | 35.21% | 120.05% | $0.83 | $54.12 |
| 2026-05-06 | 35.22% | 120.05% | $0.83 | $54.60 |
| 2026-05-05 | 34.30% | 121.06% | $0.84 | $53.24 |
| 2026-05-04 | 27.66% | 131.87% | $0.69 | $55.46 |
| 2026-05-03 | 27.66% | 131.87% | $0.69 | $54.06 |
| 2026-04-30 | 26.03% | 134.86% | $0.70 | $53.91 |
| 2026-03-18 | 25.01% | N/A | N/A | $55.43 |
| 2026-03-17 | 29.88% | N/A | N/A | $56.05 |
Recent News
- Centene, Deckers and 14 Other 'Dividend Hopefuls'Barrons.com
- StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst callsThe Fly
- BioMarin drug acquired in buyout misses goal in rare disease studyBioPharma Dive
- BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 DeficiencyPR Newswire
- BioMarin acquires Amicus Therapeutics for $4.8bnPharmaceutical Technology
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Biomarin Pharmaceutical Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Biomarin Pharmaceutical Inc (BMRN) has a next-year EPS growth estimate of 34.19%, based on analyst consensus.
When was the latest EPS estimate revision for BMRN?▾
The most recent revision occurred on 2026-06-02, when analysts adjusted the next-year EPS growth estimate from 34.00% to 34.19%.
What sector and industry does Biomarin Pharmaceutical Inc belong to?▾
Biomarin Pharmaceutical Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BMRN appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Biomarin Pharmaceutical Inc (BMRN) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports